Novel Tau Interaction Partners as Potential Biomarkers and Therapeutic Targets in Neurodegenerative Diseases

Fifteen novel human tau-interacting proteins were identified by yeast two-hybrid screening, binding full-length tau or its N-terminus, microtubule-binding domain, or C-terminus fragments.

• Why it matters: Pathological tau accumulation underlies neurofibrillary tangles, but the tau interactome in health versus disease remains incompletely defined, limiting biomarker and target discovery.
• What they did: Using yeast two-hybrid with a human brain cDNA library, the study screened for tau partners and then validated interactions with in vitro co-immunoprecipitation and colocalization using physiological and pathological tau isoforms.
• The result: Surface plasmon resonance supported these tau interactions, and in silico interactome analysis linked the partners to additional downstream processes relevant to neurodegenerative pathways, enabling new therapeutic and biomarker candidates.

AI summary of the abstract · may contain errors · not medical advice · read the paper.